Dean-tu Alzheimer's phase II / III clinical missed the primary end point of the trial
-
Last Update: 2020-02-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Ad is one of the most serious diseases threatening human health, and powdery protein is the most promising target Powdery protein is not only the most important pathological feature of AD, but also has human genetic support and is related to the pathogenesis of AD But so far, four powdery protein antibodies have failed in nine three phases of clinical trials, and four bace (beta secretase) inhibitors and three Gama secretase inhibitors have shown deterioration of the disease Both antibodies failed in several larger phase III clinical trials, and Solan's failure at Thanksgiving three years ago hurt Lilly However, because these subjects are not single enough, they may miss the best intervention time, the dose is not maximized, and the tracking time is also short, so there is today's long-term tracking test in ADAD.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
